Human Endogenous Retroviruses as Pathogenic Factors in the Development of Schizophrenia. by Slokar, Gorjan & Hasler, Gregor
January 2016 | Volume 6 | Article 1831
Review
published: 11 January 2016
doi: 10.3389/fpsyt.2015.00183
Frontiers in Psychiatry | www.frontiersin.org
Edited by: 
Francisco Ciruela, 
Universitat de Barcelona, Spain
Reviewed by: 
Christoph Anacker, 
Columbia University, USA 
Luis F. Callado, 
University of the Basque Country, 
Spain
*Correspondence:
Gregor Hasler  
gregor.hasler@puk.unibe.ch, 
g.hasler@bluewin.ch
Specialty section: 
This article was submitted to 
Neuropharmacology, 
a section of the journal 
Frontiers in Psychiatry
Received: 26 October 2015
Accepted: 15 December 2015
Published: 11 January 2016
Citation: 
Slokar G and Hasler G (2016) Human 
Endogenous Retroviruses as 
Pathogenic Factors in the 
Development of Schizophrenia. 
Front. Psychiatry 6:183. 
doi: 10.3389/fpsyt.2015.00183
Human endogenous Retroviruses 
as Pathogenic Factors in the 
Development of Schizophrenia
Gorjan Slokar and Gregor Hasler*
Psychiatric University Hospital, University of Bern, Bern, Switzerland
Schizophrenia is a complex disorder, characterized by the interplay between genetic 
and environmental factors. Human endogenous retroviruses (HERVs), genetic elements 
that originated from infections by exogenous retroviruses millions of years ago, comprise 
~8% of the human genome. Here, we provide a comprehensive review of accumulating 
evidence, detailing HERV aberrancies associated with schizophrenia. Studies examining 
the genome, transcriptome, and proteome of individuals with schizophrenia provide data 
that support the association of these viral elements with the disorder. Molecular differ-
ences can be found within the central nervous system and peripheral tissues. However, 
additional studies are needed to substantiate the reported link and to address several 
discrepancies among previous investigations. We further discuss potentially relevant 
pathogenic mechanisms to the development of schizophrenia.
Keywords: schizophrenia, human endogenous retrovirus, HeRv-w, pathogenesis, gene–environment interaction, 
infectious
iNTRODUCTiON
The pathogenesis of schizophrenia is presently hypothesized to involve complex interactions between 
genetic and environmental factors (1). Occurrence of such interactions during critical phases of 
human neurodevelopment is thought to underlie disease initiation (2). Recent efforts have identified 
numerous candidate gene loci that confer increased susceptibility to this devastating disorder (3–5). 
Considering environmental influences, infectious agents have long been suspected to be involved 
in the etiology of schizophrenia (6), and accumulating evidence supports this theory. Being born 
during winter and spring (7) and living in relatively more urbanized areas (8) are both linked to an 
increased risk of exposure to infectious pathogens and to the development of schizophrenia. Prenatal 
maternal infections by Toxoplasma gondii, influenzavirus, and HSV-2 heighten the child’s risk of 
being diagnosed with the disorder at a later stage in life (9). Inflammatory markers associated with 
infection are elevated in peripheral blood (10) and cerebrospinal fluid (CSF) samples of subjects with 
schizophrenia (11), and occurrence of higher values of certain cytokines during childhood increases 
the probability of developing psychosis as a young adult (12). Moreover, several gene loci associated 
with schizophrenia are found in genomic regions that determine the response of the immune system 
to pathogens (4). However, the mechanism by which diverse infectious agents might be involved 
in the etiology of schizophrenia has not yet been identified. In this review, we summarize evidence 
regarding a possible missing link between infectious pathogens and schizophrenia: the so-called 
human endogenous retroviruses (HERVs).
Endogenous retroviruses (ERVs) are endogenous viral elements that are derived from past 
infections of germ cells by exogenous retroviruses. The first infection of a human ancestor by an 
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TABLe 1 | Genetic studies on HeRvs in schizophrenia.
Study Subjects Target sequence Main findings
Deb-Rinker et al. (34) 3 Monozygotic twin pairs discordant 
for schizophrenia
Retroviral pol SZRV-1a identified by representational difference analysis
Yolken et al. (37) Schizophrenia c-myc pseudogene Pseudogene present in some affected subjects
Healthy controls
Deb-Rinker et al. (35) 8 Schizophrenia SZRV-2 No differences detected
21 Healthy controls
Otowa et al. (38) 17 Schizophrenia HERV-K115 HERV-K115 presence not increased. Tendency toward increased 
presence in subjects with younger onset (p = 0.057)181 Healthy controls
Dickerson et al. (39) 229 Schizophrenia HERV-K18 SNPsb Haplotype associated with type 2 diabetes in SZ (p < 0.001, odds 
ratio = 9)136 Healthy controls
Nyegaard et al. (40) 750 Schizophrenia HERV-K18 SNPs No association with type 2 diabetes. Tendency toward association 
with type 2 diabetes in younger schizophrenia subjects (p = 0.18)1214 Healthy controls
Perron et al. (36) 59 Schizophrenia HERV-W env (MSRVc) Copy number of HERV-W env reduced in schizophrenia 
(p < 0.001) and bipolar disorder (p = 0.001)110 Bipolar disorder
105 Healthy controls
Here, we present a summary of genetic studies, examining genetic differences directly or indirectly relating to HERVs in individuals with schizophrenia and healthy controls. “Target 
sequence” denotes the sequences of the human genome used for PCR.
aSchizophrenia-associated retrovirus 1.
bSingle nucleotide polymorphisms.
cMultiple sclerosis-associated retrovirus.
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exogenous retrovirus is estimated to have taken place around 
100 million years ago (13). Many more integration events have 
occurred since, until possibly as recently as 100,000 years ago (14), 
which has resulted in HERVs comprising about 8% of the present 
human genome, distributed over several hundred thousand loci 
(15). Given the time scale of these integrations, currently, these 
elements are shared among different human populations, with 
only a few loci displaying insertional polymorphisms (presence/
absence) (16, 17). Nearly all HERVs have accumulated mutations 
that prevent them from forming infectious virions or retro-
transposing within the cell. Epigenetic silencing mechanisms 
further interfere with these processes, therefore, the inheritance 
of HERVs is limited to the classical Mendelian pattern. HERVs 
can be grouped into three classes, according to their similarities 
with existing exogenous retrovirus genera. Class I, Class II, and 
Class III contain Gammaretrovirus-like, Betaretrovirus-like, and 
Spumavirus-like HERVs. They can be further classified into 
“Families,” based on varying criteria such as sequence similarity 
or primer-binding sites. HERV classification has been extensively 
reviewed (18–20). HERVs exhibit the same basic gene structure 
as do exogenous retroviruses: 5′-LTR-gag-pro-pol-env-LTR-3′. 
The long terminal repeats (LTRs) contain promoter and enhancer 
sequences, necessary for transcription. Gag, pro, pol, and env 
encode the different proteins needed for the retroviral life cycle. 
However, most HERVs simply consist of a solitary LTR, missing 
the retroviral genes and the second LTR. Such HERVs are believed 
to have originated from homologous recombination of 5′ and 3′ 
LTRs. Several physiological functions of HERVs have started to 
be recognized in recent years. Recombination events involving 
HERVs have contributed substantially to the current structure of 
the human genome (21). LTRs of retroviral elements have been 
incorporated into the regulatory region of human genes to serve 
as promoters or enhancers (22). Apart from their significance for 
protein-coding genes, the role of HERVs in the evolution and 
regulation of non-coding RNAs is increasingly being recognized 
(23). In addition to their importance at the DNA level, HERVs 
themselves are also transcribed into RNA, depending on tissue 
type and the developmental stage (24, 25). The physiological 
significance of most of these transcripts has not yet been clearly 
established. Some transcripts are translated into proteins and 
perform essential functions in the host. The most well-studied 
instance is the function of env-derived proteins in the formation 
of the syncytiotrophoblast (26). HERV protein expression can 
also be observed in other tissues of healthy human individuals; 
however, the physiological role of these proteins has not yet been 
elucidated (27–29).
HeRvs AND SCHiZOPHReNiA
Human endogenous retrovirus have been implicated in various 
diseases, such as cancer (30), autoimmune diseases (31–33), and 
neuropsychiatric illnesses. In the following summary, we will 
focus on HERV-related findings in schizophrenia. Our summary 
is structured based on the molecular focus of each study (genet-
ics, RNA expression, protein expression, and antibodies), and the 
different tissues investigated (brain, CSF, leukocytes, or plasma/
serum).
DNA Studies
DNA studies focusing on the role of HERVs in schizophrenia 
have tried to determine whether subjects with schizophrenia 
possess unknown HERV insertions/deletions or known 
polymorphisms correlate with the disease; an overview of the 
included studies has been presented in Table 1. In a study of 
three monozygotic twin pairs discordant for schizophrenia, 
a sequence designated schizophrenia-associated retrovirus 
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1 (SZRV-1) was amplified by polymerase chain reaction 
(PCR). Subsequent application of representational difference 
analysis yielded increased quantities of this sequence in all 
three affected twins (34). The observed sequence exhibited 
high similarity to the multiple sclerosis-associated retrovirus 
(MSRV). Three other sequences were further amplified, which 
were not increased in all the affected twins. When one of these 
sequences, termed SZRV-2, was used as a probe for Southern 
blot, the detection rate did not differ between eight subjects 
and their matched controls (35). Investigation of HERV-W env 
(MSRV subtype) copy number by real-time polymerase chain 
reaction (qPCR) in 59 subjects with schizophrenia revealed a 
significantly reduced copy number in the subjects compared to 
healthy controls (36).
A study investigating HERV-K115, a member of the HERV-
K(HML-2) family displaying insertional polymorphism, found 
no association between HERV-K115 and schizophrenia (38). 
However, subjects with younger-onset schizophrenia exhibited a 
higher frequency of this retroviral element (38). On examining 
single nucleotide polymorphisms (SNPs) within the HERV-K18 
locus in 229 schizophrenia subjects, one study found that a haplo-
type of two SNPs increased the risk of developing type 2 diabetes 
(odds ratio = 9) (39). A weaker association with type 2 diabetes 
was also found for several other SNPs of this locus (39). Another 
study could not confirm this association in a sample of 750 schizo-
phrenia subjects, but observed a tendency toward an increased 
type 2 diabetes risk in subjects with younger-onset schizophrenia 
(40). They also found no association between any of the measured 
SNPs and an increased risk of developing schizophrenia.
Examination of the DNA of individuals with schizophrenia 
for the presence of processed pseudogenes of the c-myc tran-
scription factor, which have not been detected in the genome 
of healthy individuals, revealed the presence of pseudogenes in 
some individuals with schizophrenia, while none were observed 
in healthy controls (37). Processed pseudogenes arise from the 
reverse transcription and integration of cellular messenger RNA 
into the nuclear DNA by retrotransposons.
RNA Studies
An overview of the RNA studies has been presented in Table 2. In 
a study of brain tissue obtained from four schizophrenia subjects, 
application of primers specific for the retroviral pol region revealed 
that 45% of transcripts in schizophrenia subjects were homolo-
gous to HERV-W (MSRV) compared to 10% in controls (37). A 
subsequent study found the level of HERV-W transcripts to be sig-
nificantly increased and that of ERV9 transcripts to be significantly 
decreased in the frontal cortex of five schizophrenia subjects (41). 
In a microarray study involving 35 schizophrenia subjects and 35 
bipolar disorder subjects, no differences were found in the levels 
of HERV-W or ERV9 transcripts between subjects and controls; 
however, HERV-K10 transcripts were significantly increased in 
individuals with schizophrenia and bipolar disorder (42). Reverse 
transcription-polymerase chain reaction (RT-PCR) was also 
applied, targeting different HERV env sequences, and found no 
differences between samples obtained from healthy controls and 
individuals with schizophrenia (42). To evaluate the effect of psy-
chiatric medication on HERV transcription, one study measured 
HERV RNA in different cell lines and in 18 brain samples obtained 
from subjects with schizophrenia and 20 brain samples obtained 
from subjects with bipolar disorder. Valproic acid (VPA) was found 
to induce increased RNA expression of certain HERVs in vitro with 
a particularly strong effect on the RNA expression of HERV-W 
and ERV9, but not on HERV-K (43). Tested antipsychotics had a 
minimal impact on HERV transcription (43). In the same study, 
ERV9 transcripts were significantly elevated in schizophrenia, 
and ERV9 and HERV-K (HML-2) transcripts were significantly 
elevated in bipolar disorder, compared to that observed in healthy 
controls independent of VPA treatment. HERV-W expression was 
not associated with schizophrenia or bipolar disorder. However, 
VPA-treated schizophrenia subjects exhibited significantly 
elevated HERV-W RNA levels, compared to those observed in 
untreated schizophrenia subjects. No such association could be 
found in VPA-treated bipolar disorder subjects.
In a study of CSF samples obtained from 35 subjects with 
recent-onset schizophrenia and 20 subjects with chronic schizo-
phrenia, HERV RNA was detected in 10/35 subjects of the former 
group, 1/20 subjects of the latter group, and in none of the subjects 
of the non-inflammatory neurologic disease and healthy control 
group. The sequences identified belonged to the HERV-W, ERV9, 
and HERV-FRD families, with HERV-W constituting the major-
ity of the sequences, and were reported to be particle-associated 
(41). Illness duration and symptom severity were not associated 
with the increase in HERV transcripts.
Based on their findings in the CSF, the presence of retroviral 
gag sequences was examined in the plasma samples of 54 recent-
onset schizophrenia subjects. Particle-associated HERV-W RNA 
was found in 9/54 subjects and 2/46 controls (44). Five of the 
nine subjects whose plasma tested positive for particle-associated 
HERV-W RNA were also previously found to harbor retroviral 
RNA in their CSF, while only three subjects whose CSF tested 
negative for particle-associated HERV-W RNA were found 
to harbor retroviral RNA in their plasma. HERV-W-positive 
subjects showed a tendency toward increased acuity of psychotic 
symptoms (p = 0.06). Medication intake was not associated with 
HERV status. Another study detected HERV-W env RNA in the 
plasma of 42/118 recent-onset schizophrenia subjects, and in 
none of the controls (47).
ERV9 RNA was detected in the leukocytes of 20/58 subjects 
with recent-onset schizophrenia and 0/38 healthy controls (45). 
Another study tested peripheral blood monocular cells (PBMCs) 
of 30 first-episode schizophrenia subjects for the presence of 
HERV-W env and gag sequences. Multiple HERV-W elements 
were transcribed in both groups. gag transcripts were increased 
twofold in subjects with schizophrenia compared to those in 
healthy controls (46). A HERV-W element on 11q13.5 was identi-
fied as the main contributor. This element is inserted into the sec-
ond intron of the putative gene PTD015. No differences were seen 
in env transcripts. gag transcripts exhibited a significant inverse 
relationship with illness duration. Symptom severity and medica-
tion intake was not associated with increased gag transcripts. The 
state of activation of PBMCs was further assessed by measuring 
the transcripts of two genes involved in metabolic pathways; how-
ever, no differences were found between schizophrenia subjects 
and healthy controls. Moreover, lymphocyte culture stimulation 
TABLe 2 | Transcriptome studies on HeRvs in schizophrenia.
Study Subject(s) Specimen Target sequence Main findings
Brain (postmortem)
Yolken et al. (37) 4 Schizophrenia Frontal cortex Retroviral pol Increased HERV-W (MSRV) in schizophrenia. Increased 
HERV-K10 in bipolar disorder4 Bipolar disorder
6 Healthy controls
Karlsson et al. (41) 5 Schizophrenia Frontal cortex Retroviral pol Increased HERV-W (p < 0.0001). Significantly decreased 
ERV9 (p < 0.0001)6 Healthy controls
Frank et al. (42) 35 Schizophrenia Prefrontal 
cortex
Retroviral pol Increased HERV-K10 in schizophrenia (p < 0.05) and 
bipolar disorder (p < 0.01)35 Bipolar disorder
35 Healthy controls
7 Schizophrenia HERV-W env, 
HERV-FRD env, 
HERV-K env
No significant differences
7 Healthy controls
Diem et al. (43) 18 Schizophrenia Prefrontal 
cortex
HERV-W pol, 
ERV9 pol, HERV-
K(HML-2) gag
ERV9 increase in schizophrenia (p < 0.01). ERV9 and 
HERV-K(HML-2) increases in bipolar disorder (p < 0.01)20 Bipolar disorder
18 Healthy controls Increases independent of medication
CSF
Karlsson et al. (41) 35 Recent-onset schizophrenia or  
recent-onset schizoaffective disorder
Cell-free 
supernatant
Retroviral pol Increased HERV-W, ERV9 and HERV-FRD expression 
(p < 0.001) 10/35, 1/20, 0/22, 0/30
20 Chronic schizophrenia or chronic 
schizoaffective disorder
22 Non-inflammatory neurologic disease
30 Healthy controls
Blood
Karlsson et al. (44) 54 Recent-onset schizophrenia or recent-
onset schizoaffective disorder or recent-
onset schizophreniform disorder
Plasma Retroviral gag Increased HERV-W (p = 0.05) 9/54, 0/30
46 Healthy controls
Huang et al. (45) 58 Recent-onset schizophrenia Leukocytes Retroviral pol Increased ERV9 (p < 0.01) 20/58, 0/38
38 Healthy controls
Yao et al. (46) 30 Recent-onset schizophrenia
26 Healthy controls
PBMCsa HERV-W env, gag 2.1-fold increase in gag, mainly from the element on 
11q13.5 (p < 0.01). No env increase
Huang et al. (47) 118 Recent-onset schizophrenia Plasma HERV-W env Increased HERV-W env (p < 0.01) 42/118, 0/106
106 Healthy controls
Perron et al. (36) 45 Schizophrenia PBMCs HERV-W env Increased transcripts in schizophrenia (p = 0.01) and 
bipolar disorder (p < 0.0001). Association remained after 
exclusion of VPA-treated subjects
91 Bipolar disorder
73 Healthy controls
Here, we present a summary of studies examining differences in HERV transcription in individuals with schizophrenia in comparison to healthy controls. The table is divided into 
studies examining brain, CSF, and blood samples. “Specimen” denotes the exact origin/processing of samples. “Target sequence” denotes the sequence of the retroviral genome 
that was used for PCR.
aPeripheral blood monocular cells.
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from three blood donors did not affect transcripts of the HERV-W 
gag gene detected in schizophrenia subjects. Exploration of the 
presence of HERV-W (MSRV) env sequences in PBMCs of 45 
individuals with chronic schizophrenia revealed a significant 
increase in transcripts compared to that observed in controls 
and a significant decrease compared to that observed in bipolar 
disorder subjects (36). The association remained after exclusion 
of VPA-treated subjects. No association of HERV transcripts 
was found with illness duration or symptom severity. However, 
seropositivity against T. gondii was significantly increased in 
HERV-W-positive bipolar disorder and schizophrenia subjects, 
merged as a single group. Seropositivity against Herpes simplex 
virus 1/2 and Cytomegalovirus did not correlate with HERV-W 
detection.
Protein Studies
An overview of the protein studies has been presented in Table 3. 
Reverse transcriptase activity was measured in the cerebellum 
of 12 schizophrenia subjects by the product-enhanced reverse 
transcriptase assay and found to be significantly increased 
compared to that in the controls (37). Significantly decreased 
levels of HERV-W GAG proteins were detected in the anterior 
cingulate gyrus and the hippocampus of 15 schizophrenia, 15 
bipolar disorder, and 15 major depressive disorder subjects by 
immunohistochemistry (28). GAG proteins were expressed in 
neurons and astroglial cells. Analysis of GAG by western blotting 
yielded multiple bands, leading the researchers to conclude that 
multiple HERV-W elements contribute to this expression. The 
number of immune cells in brain tissue did not differ between 
subjects and controls. No association could be found between 
HERV-W GAG expression and serological status for T. gondii, 
Herpes simplex virus 1/2, and Cytomegalovirus.
In serum samples, HERV-W GAG proteins were found in 
24/49 individuals with schizophrenia and 2/49 controls, and 
HERV-W ENV in 23/49 individuals with schizophrenia and 
1/30 controls (49). Detection of both proteins significantly 
TABLe 3 | HeRv protein studies in schizophrenia.
Study Subjects Specimen Target Main findings
Brain (postmortem)
Yolken et al. (37) 12 Schizophrenia Cerebellum Reverse transcriptase Increased reverse transcriptase activity in 
schizophrenia (p = 0.01) and non-psychotic 
depression (p < 0.05)
12 Bipolar disorder
11 non-psychotic depression
12 Healthy controls
Weis et al. (28) 15 Schizophrenia Anterior cingulate gyrus, 
hippocampus
HERV-W GAG Significant reduction of GAG in all subject groups 
(p ≤ 0.05)15 Bipolar disorder
15 Major depressive disorder
15 Healthy controls
Blood
Perron et al. (49) 49 Schizophrenia Serum HERV-W GAG HERV-W GAG positive in 24/49 subjects, 2/49 
controls (p < 0.001) 49 Healthy controls
49 Schizophrenia HERV-W ENV HERV-W ENV in 23/49 subjects, 1/30 controls 
(p < 0.01) 30 Healthy controls
35 Schizophrenia CRPa CRP correlation with ENV (p < 0.001) and GAG 
(p < 0.05) antigenemia49 Healthy controls
Huang et al. (47) 118 Recent-onset schizophrenia Serum Reverse transcriptase Increased reverse transcriptase activity (p < 0.05) 
40/118, 3/106106 Healthy controls
Here, we present a summary of studies examining differences in protein expression relating to HERVs in schizophrenia subjects in comparison to healthy controls. The table is 
divided into studies examining brain and blood samples. “Specimen” denotes the exact origin/processing of the samples. “Target” denotes the retroviral protein assayed in the study.
aC-reactive protein.
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correlated with C-reactive protein (CRP) levels. Medication 
intake was not associated with seropositivity for HERV-W pro-
teins. Measurement of reverse transcriptase activity in the serum 
of recent-onset schizophrenia subjects by quantitative reverse 
transcription PCR (RT-qPCR) yielded activity of this enzyme in 
40/118 schizophrenia subjects and 3/106 controls (47).
Antibody Studies
Antibodies directed against a particular retroviral antigen can 
bind to homologous proteins of related retroviruses. Protein 
antigens of readily available retroviruses can, therefore, be used 
to detect antibodies directed against unidentified retroviruses. 
An overview of antibody studies has been presented in Table 4. 
HIV-1 western blot assay was applied to screen 38 schizophrenia 
subjects for the presence of retroviral antibodies. Antibodies were 
present in 21/38 subjects and 4/16 controls (50). Application of 
protein antigens of the betaretroviruses Mason-Pfizer monkey 
virus (MPMV), mouse mammary tumor virus (MMTV), simian 
retrovirus 5 (SRV-5), and Gammaretrovirus baboon endogenous 
virus (BaEV) revealed a significantly increased incidence of 
antibodies against MPMV, BaEV, and SRV-5 in 17 first-episode 
schizophrenia subjects (51). The largest differences were seen 
in antibodies against MPMV. The authors, therefore, assessed 
antibody levels against this species by immunoassay and immu-
noblot in 38 first-episode schizophrenia subjects and found 
that 11/38 subjects and 1/27 controls had antibodies above the 
set threshold (51). Follow-up of four seropositive subjects after 
1  year revealed that two had reverted to a seronegative status 
and optical densities were diminished in the other two subjects. 
Using MPMV, the Gammaretrovirus murine leukemia virus 
(MuLV) and the Lentivirus feline immunodeficiency virus (FIV), 
significantly increased antibody levels against MPMV and MuLV 
were detected in 163 subjects with recent-onset psychosis, but 
not in 268 multi-episode schizophrenia subjects (52). These were 
directed against gag, pol, and env encoded proteins. Since the 
authors could not find any nucleic acids of the tested retroviruses 
in the subject sera and multiple regions of homology for both 
retroviruses were found within the human genome, they con-
cluded that the detected antibodies likely arose from activation 
of homologous HERVs. Increased antibodies were not associated 
with symptom severity, illness duration, or medication intake. 
Antibodies against the ERV9 family were measured by in vitro 
expression of ERV9 POL proteins. Antibodies were present in the 
sera of some subjects, who also tested positive for ERV9 RNA, 
and absent in the sera of controls (45).
Potential Contributions of HeRvs to the 
Pathogenesis of Schizophrenia
Different downstream effects of increased HERV activation 
may be involved in the pathogenesis of schizophrenia. Pro-
inflammatory properties of HERV DNA, RNA, or proteins may 
be at the root of the immune aberrancies observed in individuals 
with schizophrenia. Normally, the immune response against 
viruses involves the detection of viral DNA and RNA within the 
cell. It has been proposed that HERV DNA and/or RNA might 
also activate such pathways (53). Such a mechanism is supported 
by a recent study, which details the exploitation of endogenous 
retroviral transcripts by the immune system, to induce a humoral 
immune response without the help of T-cells (54). More definite 
evidence has been obtained regarding the pro-inflammatory 
effects of HERV proteins. HERV-W ENV has been shown to 
induce an innate immune response via interaction with Toll-like 
receptor 4 (TLR4) and promote a TH1-like response, stimulating 
the release of IL-6, TNF-α, and IL-1β (55). The same protein also 
generates cytokine production in astroglial cells, induces death 
of oligodendrocytes, and may evoke superantigen-like effects 
(56, 57). In  vivo, ENV and GAG antigenemia within serum 
TABLe 4 | Retroviral antibodies in schizophrenia.
Study Subjects Target Main findings
Hart et al. (50) 38 Schizophrenia HIV-1 Increased antibodies to HIV-1 antigens in SZ (p = 0.05) 21/38, 4/16
16 Healthy controls
Lillehoj et al. (51) 15 Recent-onset schizophrenia MPMVa GAG, BaEVb ENV/GAG, 
MMTVc GAG, SRV-5d GAG
Increased incidence of antibodies to MPMV (p < 0.001), BaEV 
(p < 0.05), and SRV-5 (p < 0.05) antigens27 Healthy controls
38 Recent-onset schizophrenia MPMV GAG Increased antibody levels against MPMV (p < 0.01) 11/38, 1/27
27 Healthy controls
Huang et al. (45) 58 Recent-onset schizophrenia ERV9 POL Antibodies present in some ERV9 RNA-positive subjects
38 Healthy controls
Dickerson et al. (52) 163 Recent-onset psychosis MuLVe, MPMV, FIVf Increased antibodies to MuLV and MPMV in recent-onset psychosis 
(p < 0.001). No increase in multiple-episode schizophrenia268 Multiple-episode schizophrenia
235 Healthy controls
Here, we present a summary of studies examining the presence of retroviral antibodies in schizophrenia subjects and healthy controls. “Target” denotes the retroviruses/retroviral 
proteins used to assay the presence of antibodies.
aMason-Pfizer monkey virus.
bBaboon endogenous virus.
cMouse mammary tumor virus.
dSimian retrovirus 5.
eMurine leukemia virus.
fFeline immunodeficiency virus.
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significantly correlate with CRP levels (49). Multiple studies have 
repeatedly linked an increase in CRP, IL-6, TNF-α, and IL-1β to 
schizophrenia (10, 58), supporting inflammatory processes such 
as HERV-W-related ones being involved in the pathogenesis of 
this severe disorder.
Apart from its inflammatory effects, several other properties of 
HERV-W ENV have been proposed to be involved in the patho-
genesis of schizophrenia. The human sodium-dependent neutral 
amino acid transporter type 1 (hASCT1) and hASCT2 have been 
established as the cellular receptors of HERV-W ENV (59). Both 
receptors play a role in the regulation of glutamatergic transmis-
sion in the brain (48), which has been found dysfunctional in 
schizophrenia. It has, therefore, been speculated that HERV-W 
ENV might contribute to schizophrenia by disturbing these 
pathways (44). Cell cultures infected by exogenous retroviruses, 
using an allelic receptor, do indeed exhibit impaired transport 
of the amino acids glutamine and alanine (60). Furthermore, a 
significant decrease in immunoreactivity of hASCT1 has been 
observed in neurons and astroglial cells of the cingulate cortex 
and hippocampus in individuals with schizophrenia, possibly 
reflecting occupation of the receptor by HERV-W ENV or recep-
tor downregulation (48). Expression of HERV-W env in human 
glioma cells results in a two- to fourfold increase in expression 
of brain-derived neurotrophic factor (BDNF), neurotrophic 
tyrosine kinase receptor type 2 (NTRK2), and dopamine receptor 
D3 (DRD3) (47). BDNF aberrancies have been repeatedly associ-
ated with schizophrenia (61). In addition, the small conductance 
Ca2+-activated K+ channel protein 3 (SK3), which has been linked 
to schizophrenia as well, is also increased after expression of 
HERV-W env within neuroblastoma cells (62). Rats, receiving 
bilateral injections of recombinant HERV-W ENV protein into 
the ventral region of the hippocampus, exhibit several neurologi-
cal and behavioral abnormalities associated with schizophrenia, 
including increased sensitivity to the psychostimulant MK-801, a 
common feature of animal models of schizophrenia, and a strong 
emergence of stereotypic behaviors, which are associated with 
some schizophrenia subtypes (63).
Aside from the effects of HERV products, HERVs might also 
contribute to schizophrenia via their regulatory effects on cellular 
genes. One HERV-W element was identified within the regula-
tory region of the GABA receptor B1 gene GABBR1, which is 
down-regulated in schizophrenia (64). A HERV-K(HML-2) ele-
ment was confirmed to act as an enhancer for the schizophrenia-
associated gene PRODH (65). It has been hypothesized that 
increased activity of one HERV element may lead to widespread 
epigenetic silencing of the whole respective HERV family, result-
ing in aberrant quantities of cellular proteins whose transcription 
is controlled by the individual HERV elements, such as GABA 
receptor B1.
In addition to their significance for protein-coding genes, the 
role of HERVs in the regulation of non-coding RNA potentially 
constitutes another pathogenic mechanism. HERVs are associ-
ated with a large number of long non-coding RNAs (lncRNAs), 
where they mainly overlap with transcriptional start sites (66). 
LncRNAs have a broad spectrum of biological activities, e.g., they 
can affect transcription, chromatin state, or splicing patterns, and 
are thought to be of particular importance in brain development 
(67). Evidence is emerging for an involvement of these molecules 
in disorders of the brain, including schizophrenia (68–70). It 
remains to be demonstrated whether any of the HERV transcripts 
observed in individuals with schizophrenia constitute functional 
non-coding RNA.
DiSCUSSiON
The most consistent evidence of an association between HERVs 
and schizophrenia comes from studies on HERV transcripts in 
blood samples of individuals with schizophrenia. Four studies 
found an increase in HERV-W transcripts, one study found an 
increase in ERV9 transcripts. Studies in postmortem brain tissue 
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and CSF of schizophrenia subjects partly confirm these findings 
in blood. One study in CSF found increased HERV-W transcripts. 
Three studies in brain tissue found increased HERV-W, increased 
HERV-K10, and increased ERV9 transcripts. One possible reason 
for discrepancies regarding the associated HERV families in all of 
these studies may be related to technical differences and the high 
copy number of HERVs within the human genome. The HERV-W 
family is comprised of an estimated 250 elements and nearly all 
of these contain mutations, such as stop-codons, frame-shifts, or 
deletions (71). This sequence heterogeneity makes it very difficult 
to design primers for PCR, to amplify all members of a particular 
HERV family (24). Owing to the use of distinct primers in each 
study, different subsets of HERVs were likely amplified.
Four studies targeting retroviral proteins confirm findings of 
differential HERV activity at the protein level. Two studies found 
an increased reverse transcriptase activity, which is unspecific to 
any particular HERV family. One study found decreased HERV-W 
GAG, while another study found increased HERV-W GAG and 
ENV. Causes for decreased HERV-W GAG protein levels in 
the brain of individuals with schizophrenia are unclear, given 
the increases of this protein in the blood and at the RNA level. 
The authors themselves speculate that interfering mechanisms 
by non-coding HERV transcripts, disrupting the translation of 
coding transcripts, may yield an explanation (28).
Findings of HERV RNA and proteins in individuals with 
schizophrenia are further corroborated by the consistent detection 
of retroviral antibodies in this population. Four studies detected 
increased antibody levels to a Lentivirus, betaretroviruses, 
gammaretroviruses, and to the Gammaretrovirus-like ERV9. 
Considering evidence detailing HERV abnormalities associated 
with schizophrenia and the lack of evidence of an involvement 
of exogenous retroviruses in schizophrenia so far, it appears 
very likely that these antibodies are directed against HERVs. 
These antibody studies may additionally provide evidence for an 
involvement of the Betaretrovirus-like HERV-K in schizophrenia, 
since only one RNA study found an association with HERV-K. 
However, the detected antibodies against betaretroviruses may 
also simply be a result of cross-reactivity between antibodies 
against the Gammaretrovirus-like HERV-W or ERV9.
There is some evidence, indicating copy number variations of 
HERV-W in schizophrenia. One study using representational dif-
ference analysis found an increase in copy number, while another 
using qPCR found a decrease. Both studies suggest genomic 
alterations in schizophrenia subjects; however, more conclusive 
research is needed in this area.
There is preliminary evidence for the existence of c-myc 
pseudogenes in schizophrenia subjects. Although these have only 
been found in one study, they are of potential interest because this 
gene is mainly expressed during fetal development and may, thus, 
provide insights into the temporal development of environmental 
and genetic contributions to schizophrenia (37). These findings 
may, however, not only point to an involvement of HERVs but 
also point to the action of other retrotransposons, such as long 
interspersed nuclear elements (LINEs), also shown to be increas-
ingly active in schizophrenia (37, 72).
Association of increased HERV activity with illness dura-
tion of schizophrenia subjects is debatable. Based on the initial 
findings in CSF, which were limited to recent-onset schizophre-
nia subjects, subsequent studies focused on subjects in the early 
symptomatic disease stages. Retroviral antibodies also seem 
to be exclusively found at disease onset. However, two studies 
analyzing the blood of chronic schizophrenia subjects and four 
post-mortem brain studies detected HERV abberrancies in 
later disease stages. Three studies found no association between 
illness duration and HERV expression/antibodies, while one 
study found an inverse relationship between illness duration 
and HERV RNA levels.
One in vitro study reported the influence of VPA on the tran-
scription of HERV-W and ERV9. Two of six in vivo studies found 
an association between VPA intake and HERV-W expression, 
while the other four did not report any association. However, only 
one of these four studies separately analyzed different psychiatric 
drugs. The association of HERV-W with schizophrenia remained 
in one of the two positive studies after exclusion of subjects 
treated with VPA. It appears that VPA contributes, in part, to the 
HERV-related phenomena observed in schizophrenia. Future 
research will have to assess previous and current VPA intake to 
eliminate this confounding variable.
In vitro experiments have demonstrated that HERV expression 
can be induced by activation of monocytes (73). It has, therefore, 
been hypothesized that HERV-related findings in schizophrenia 
might simply be the result of increased immune cell activation 
or infiltration (42). However, the results of two studies in schizo-
phrenia subjects do not support this premise, since immune cell 
activation in the blood and immune cell number in the brain did 
not differ in individuals with schizophrenia. Based on research 
detailing activation of HERVs after infection of immune (74) and 
neural cells (75–77), it has been speculated that transcriptional 
deregulation of HERVs in schizophrenia might be the result of an 
initial infectious event. HERV activation has been demonstrated 
in infections by schizophrenia-associated pathogens HSV-1 
(76), T. gondii (75), and influenzavirus (76, 77). One study in 
schizophrenia subjects partially corroborates this hypothesis, 
since antibodies against T. gondii were associated with increased 
HERV-W transcripts, although no association was found with 
herpes viruses. Another smaller study in schizophrenia subjects 
could not find any association between infectious agents and 
HERV-W expression. It is important to note that HERV expres-
sion modulation in infection models is not limited to a single 
HERV family, such as HERV-W, but involves many different 
HERV families. It remains to be demonstrated whether the 
action of certain infectious agents may ultimately lead to similar 
changes in HERV expression over time, as have been observed in 
schizophrenia.
The association of HERV-W and schizophrenia is not highly 
specific. Bipolar disorder has also been associated with this HERV 
family, as has been reported in this review. Schizophrenia and 
bipolar disorder share approximately 60% of genetic risk factors 
(78) and exhibit similar brain structural abnormalities, such as 
reductions in total brain gray and white matter, and increased lat-
eral ventricular volume (79). HERV-W has also been repeatedly 
linked with multiple sclerosis (80, 81). Schizophrenia and multi-
ple sclerosis have been reported to share certain epidemiologic 
features, such as age of onset, season of birth, and geographic 
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distribution (41). However, schizophrenia, bipolar disorder, and 
multiple sclerosis also exhibit differences regarding the molecular 
characteristics of HERV-W, which may be in part responsible for 
the observed differences in phenotype. As previously reported 
in one study, the DNA copy number of HERV-W is reduced in 
schizophrenia and bipolar disorder subjects. Conversely, exami-
nation of DNA copy number of HERV-W in multiple sclerosis 
subjects revealed increased copy numbers of this HERV family 
in the diseased subjects compared to healthy controls (82). 
Furthermore, the nucleotide sequences of examined HERV-W 
DNA and RNA slightly differ among all three disorders (36), 
possibly reflecting different subsets of HERV-W elements being 
activated.
Taken together, preliminary evidence suggests that differential 
activity of some HERV families is associated with schizophrenia 
in at least a subgroup of individuals with schizophrenia. The 
most frequently associated family is Gammaretrovirus-like 
HERV-W and to a lesser extent Gammaretrovirus-like ERV9 
and Betaretrovirus-like HERV-K (HML-2). Limitations of the 
current evidence include the small number of studies, the high 
methodological heterogeneity, and the generally small study 
samples, including subjects with various diagnoses.
CONCLUSiON
Human endogenous retroviruses provide an intriguing new 
avenue of research into the constituent factors involved in schizo-
phrenia. Establishment of a possible causal relationship may lead 
to the development of new treatment strategies. Such strategies 
may involve elimination of triggering environmental factors or 
direct inhibition of HERV RNA or proteins.
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